Publication Review Summaries

1. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma

Marie-Christine Kyrtsonis et al. British Journal of Haematology 2007, 137:240-243

This publication demonstrates for the first time that baseline serum free light chains (sFLC) are strongly indicative of prognosis*. The study concludes that high FLC ratios at diagnosis were highly correlated with patient survival. This data highlights the value of measurement of sFLC in all newly diagnosed patients.

See below to request your free copy.

 

2. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

Frits van Rhee et al. Blood 2007, 110(3):827-832


This large study concludes that baseline serum free light chain concentrations are important prognostic factors* and recommends that serum free light chains should be determined in all newly diagnosed Multiple Myeloma patients. The paper concludes that a rapid reduction in serum free light chains following treatment identifies patients with an aggressive Multiple Myeloma subtype.

See below to request your free copy.

 

3. Efficient Removal of Immunoglobulin Free Light Chains by Hemodialysis for Multiple Myeloma: In Vitro and In Vivo Studies

Colin A. Hutchinson et al JASN March 2007:Vol18:No.3 pp. 886-895


This exciting paper looks at a new generation of protein leaking dialyzers and examines the possibility of removing free light chains from multiple myeloma patients during extended dialysis sessions. Five consecutive patients with dialysis-dependent acute renal failure and biopsy-proven cast nephropathy were treated with extended daily hemodialysis .Three became dialysis independent. International studies involving more patients are now being undertaken as a Phase 3 Clinical Trial.

See below to request your free copy.

 

4. Eliminate urine testing during initial investigations for monoclonal gammopathies

Fiona Kilvington, Clinical Laboratory International May 2007:3

 

* In the USA diagnostic use of this product is restricted to those stated in the product insert

References

  1. Marie-Christine Kyrtsonis, Theodoros P. Vassilakopoulos, Nicoletta Kafasi, Sotirios Sachanas, Tatiana Tzenou, Argiroula Papadogiannis, Zacharoula Galanism Christina Kalpadakis, Maria Dimou, Elias Kyriakou, Maria K. Angelopoulou, Maria N. Dimopoulou, Marina P. Siakantaris, Evangelia M. Dimitriadou, Styliani I. Kokoris, Panayiotis Panayiotidis and Gerassimos A. Pangalis
    "Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma"
    British Journal of Haematology 2007; 137:240-243

    Reference: MKG370 Quantity:

  2. Frits van Rhee, Vanessa Bolejack, Klaus Hollmig, Mauricio Pineda-Roman, Elias Anaissie, Joshua Epstein, John D. Shaughnessy Jr, Maurizio Zangari, Guido Tricot, Abid Mohiuddin, Yazan Alsayed, Gail Woods, John Crowley, and Bart Barlogie
    "High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis"
    Blood, 2007; 110(3):827-832

    Reference: MKG381 Quantity:

  3. Colin A. Hutchison, Paul Cockwell, Steven Reid, Katie Chandler, Graham P. Mead, John Harrison, John Hattersley, Neil D. Evans, Mike J. Chappell, Mark Cook, Hermann Goehl, Markus Storr, and Arthur R. Bradwell
    "Efficient Removal of Immunoglobulin Free Light Chains by Hemodialysis for Multiple Myeloma: In Vitro and In Vivo Studies"
    J Am Soc Nephrol 2007 18: 886-895

    Reference: MKG344 Quantity: